April 2025 – Clinical Trial Results

Dr. Sekar Kathiresan and Dr. C. Michael Gibson discuss “one and done” gene editing for high cholesterol by permanently inhibiting PCSK9 by about 70% to achieve an average LDL lowering of 59%.

April 14, 2025

Disclosures TBD

#ACC2025 Obesity Wrap Up:

April 14, 2025

Dr. Danielle Belardo and Dr. C. Michael Gibson discuss the PRAGUE-25 trial (catheter ablation vs. antiarrhythmics with weight management and […]

#ACC2025 Antithrmbotic / Antiplatelet Wrap Up:

April 11, 2025

Dr. Bhatt and I discuss ticagrelor reversal using bentracimab from the REVERSE-IT trial, as well as comparable efficacy and safety […]